Danaher Co. (NYSE:DHR) Shares Sold by Capital Counsel LLC NY

Capital Counsel LLC NY lowered its stake in Danaher Co. (NYSE:DHR) by 0.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,690 shares of the conglomerate’s stock after selling 167 shares during the period. Danaher accounts for 0.5% of Capital Counsel LLC NY’s holdings, making the stock its 15th biggest position. Capital Counsel LLC NY’s holdings in Danaher were worth $12,703,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the second quarter worth $25,000. nVerses Capital LLC purchased a new stake in shares of Danaher during the 2nd quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher during the 3rd quarter worth $40,000. MFA Wealth Advisors LLC purchased a new stake in Danaher during the 2nd quarter valued at about $51,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher in the 2nd quarter worth approximately $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DHR shares. Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Price Performance

DHR stock opened at $236.53 on Wednesday. The stock has a 50-day moving average price of $256.66 and a two-hundred day moving average price of $259.81. The company has a market cap of $170.84 billion, a PE ratio of 45.14, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. Danaher Co. has a 12-month low of $215.68 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm earned $2.02 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.